Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)’s share price was up 17.2% during trading on Tuesday after Robert W. Baird raised their price target on the stock from $17.00 to $18.00. Robert W. Baird currently has an outperform rating on the stock. Tabula Rasa Healthcare traded as high as $18.25 and last traded at $17.42, with a volume of 525,275 shares traded. The stock had previously closed at $14.86.

TRHC has been the topic of a number of other reports. Zacks Investment Research raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Stifel Nicolaus reaffirmed a “buy” rating and set a $16.00 target price on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Chardan Capital started coverage on shares of Tabula Rasa Healthcare in a research report on Monday, July 10th. They set a “buy” rating and a $19.50 target price on the stock. Finally, UBS AG reaffirmed a “buy” rating and set a $17.00 target price (down from $18.00) on shares of Tabula Rasa Healthcare in a research report on Thursday, May 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Tabula Rasa Healthcare has a consensus rating of “Buy” and a consensus target price of $17.67.

In related news, insider Orsula V. Knowlton sold 8,000 shares of Tabula Rasa Healthcare stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $11.94, for a total transaction of $95,520.00. Following the transaction, the insider now directly owns 919,407 shares of the company’s stock, valued at $10,977,719.58. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Glen R. Bressner acquired 7,500 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The shares were acquired at an average cost of $11.96 per share, for a total transaction of $89,700.00. Following the completion of the acquisition, the director now owns 18,256 shares of the company’s stock, valued at $218,341.76. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 46,759 shares of company stock worth $634,444. 45.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. TIAA CREF Investment Management LLC raised its position in shares of Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Tabula Rasa Healthcare by 47.2% in the second quarter. Bank of New York Mellon Corp now owns 19,412 shares of the company’s stock valued at $293,000 after buying an additional 6,228 shares during the last quarter. Cadence Capital Management LLC acquired a new position in shares of Tabula Rasa Healthcare during the second quarter valued at about $210,000. Boston Partners raised its position in shares of Tabula Rasa Healthcare by 17.1% in the second quarter. Boston Partners now owns 235,180 shares of the company’s stock valued at $3,540,000 after buying an additional 34,360 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Tabula Rasa Healthcare by 58.1% in the second quarter. Russell Investments Group Ltd. now owns 94,089 shares of the company’s stock valued at $1,415,000 after buying an additional 34,565 shares during the last quarter. 24.99% of the stock is currently owned by institutional investors.

The firm’s market cap is $299.94 million. The stock’s 50-day moving average is $14.71 and its 200 day moving average is $14.02.

Tabula Rasa Healthcare (NASDAQ:TRHC) last released its earnings results on Monday, August 7th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.06. The business had revenue of $29.70 million for the quarter, compared to analyst estimates of $27.84 million. The company’s revenue was up 32.6% on a year-over-year basis. On average, equities research analysts predict that Tabula Rasa Healthcare Inc. will post $0.41 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Tabula Rasa Healthcare Inc. (TRHC) Trading Up 17.2% Following Analyst Upgrade” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/08/tabula-rasa-healthcare-inc-trhc-trading-up-17-2-following-analyst-upgrade.html.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Receive News & Stock Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related stocks with our FREE daily email newsletter.